AMGN — Amgen Inc. stock price and chart

AMGN

Amgen Inc.Stock · HealthcareDow Jones 4.3% · Nasdaq-100 0.8% · Nasdaq Composite 0.4% · S&P 500 0.3% · Russell 1000 0.3% · US Stock Market 0.3% · Russell 3000 0.3% · MSCI World 0.2% · MSCI ACWI 0.2% · S&P 500 Equal Weight 0.2%

$377.35-1.34%

as of market close, Sep 11, 2026

☾ AH $377.65 +0.08%

PeersMRNALLYUNHJNJMRKABBV

Technical analysis2

Overlay lines0

Addendum charts0

VolumeDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD

20162019202120242026

150.0200.0250.0300.0350.0400.0050.0M$377.35

2026-09-11

Price$377.35

MA20$366.79

MA50$338.46

Vol18.9M

What would $1,000 invested in AMGN be worth today? →

AMGN returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $377.35
Change YTD: +17.65%
Next earnings: Nov 3, 2026
Market cap: 204B2016-09 124.1B2026-09 204B+64.4% over the window
Enterprise value: 248.2B
Shares outstanding: 540.6M2016-06 748.4M2026-06 540.6M-27.8% over the window
52W low: $269.77
52W high: $447.03
From 52W high: -15.59%
From 52W low: +39.88%
52W range: 61%
Beta: 0.42

Volume

Rel volume: 0.85×
30D volume: 2.6M
30D $ vol: 1.1B

Fundamentals

Sales (ttm): 38.1B2016-06 22.5B2026-06 38.1B+69.5% over the window
Sales/share: $70.462016-06 $30.032026-06 $70.46+134.6% over the window
EPS (ttm): $16.102016-06 $9.782026-06 $16.10+64.6% over the window
FCF (ttm): 10.2B2016-06 8.9B2026-06 10.2B+14.7% over the window
FCF/share: $18.822016-06 $11.852026-06 $18.82+58.8% over the window
Book value/share: $21.622016-06 $40.272026-06 $21.62-46.3% over the window
Net margin: 22.95%2016-06 33.1%2026-06 23.0%-30.6% over the window
ROE: 74.80%2016-06 24.7%2026-06 74.8%+203.2% over the window
ROA: 9.14%2016-06 9.8%2026-06 9.1%-7.2% over the window
Debt / equity: 4.44×2016-06 0.932026-06 4.44+378.7% over the window
Current ratio: 1.372016-06 3.972026-06 1.37-65.4% over the window

Growth (CAGR, ttm) · 10Y

Sales: +9.11%2025-06-30 → 2026-06-3034.9B → 38.1B (+9.1% total)+12.74%2023-06-30 → 2026-06-3026.6B → 38.1B (+43.3% total)+8.37%2021-06-30 → 2026-06-3025.5B → 38.1B (+49.5% total)+5.42%2016-06-30 → 2026-06-3022.5B → 38.1B (+69.5% total)
Net income: +32.11%2025-06-30 → 2026-06-306.6B → 8.7B (+32.1% total)+3.09%2023-06-30 → 2026-06-308B → 8.7B (+9.6% total)+8.76%2021-06-30 → 2026-06-305.7B → 8.7B (+52.2% total)+1.64%2016-06-30 → 2026-06-307.4B → 8.7B (+17.6% total)
FCF: -4.06%2025-06-30 → 2026-06-3010.6B → 10.2B (-4.1% total)+1.66%2023-06-30 → 2026-06-309.7B → 10.2B (+5.1% total)+2.72%2021-06-30 → 2026-06-308.9B → 10.2B (+14.4% total)+1.38%2016-06-30 → 2026-06-308.9B → 10.2B (+14.7% total)
Shares: +0.42%2025-06-30 → 2026-06-30538.4M → 540.6M (+0.4% total)+0.36%2023-06-30 → 2026-06-30534.9M → 540.6M (+1.1% total)-0.98%2021-06-30 → 2026-06-30567.9M → 540.6M (-4.8% total)-3.20%2016-06-30 → 2026-06-30748.4M → 540.6M (-27.8% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +31.69%2025-06-30 → 2026-06-30$12.23 → $16.10 (+31.7% total)+2.76%2023-06-30 → 2026-06-30$14.84 → $16.10 (+8.5% total)+10.37%2021-06-30 → 2026-06-30$9.83 → $16.10 (+63.8% total)+5.11%2016-06-30 → 2026-06-30$9.78 → $16.10 (+64.6% total)
Sales/share: +8.65%2025-06-30 → 2026-06-30$64.86 → $70.46 (+8.6% total)+12.34%2023-06-30 → 2026-06-30$49.70 → $70.46 (+41.8% total)+9.44%2021-06-30 → 2026-06-30$44.88 → $70.46 (+57.0% total)+8.90%2016-06-30 → 2026-06-30$30.03 → $70.46 (+134.6% total)
FCF/share: -4.46%2025-06-30 → 2026-06-30$19.70 → $18.82 (-4.5% total)+1.30%2023-06-30 → 2026-06-30$18.11 → $18.82 (+3.9% total)+3.74%2021-06-30 → 2026-06-30$15.67 → $18.82 (+20.1% total)+4.73%2016-06-30 → 2026-06-30$11.85 → $18.82 (+58.8% total)
Book value/share: +56.74%2025-06-30 → 2026-06-30$13.80 → $21.62 (+56.7% total)+19.47%2023-06-30 → 2026-06-30$12.68 → $21.62 (+70.5% total)+8.28%2021-06-30 → 2026-06-30$14.52 → $21.62 (+48.9% total)-6.03%2016-06-30 → 2026-06-30$40.27 → $21.62 (-46.3% total)
Dividend/share: -19.88%2025-06-30 → 2026-06-30$9.26 → $7.42 (-19.9% total)-3.78%2023-06-30 → 2026-06-30$8.33 → $7.42 (-10.9% total)+2.00%2021-06-30 → 2026-06-30$6.72 → $7.42 (+10.4% total)+7.56%2016-06-30 → 2026-06-30$3.58 → $7.42 (+107.3% total)
Price: +33.49%2025-09-11 → 2026-09-11$282.73 → $377.35 (+33.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+12.97%2023-09-11 → 2026-09-11$261.72 → $377.35 (+44.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+12.03%2021-09-10 → 2026-09-11$213.75 → $377.35 (+76.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+8.52%2016-09-09 → 2026-09-11$166.55 → $377.35 (+126.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +37.20%2025-09-11 → 2026-09-11$275.10 → $377.35 (+37.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+16.40%2023-09-11 → 2026-09-11$239.22 → $377.35 (+57.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+15.57%2021-09-10 → 2026-09-11$182.95 → $377.35 (+106.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+11.80%2016-09-09 → 2026-09-11$123.60 → $377.35 (+205.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 23.4×2016-09 16.362026-09 23.33+42.7% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 17.9×2016-09 13.282026-09 17.85+34.4% over the window
Fwd P/E: 16.2×
P/S (ttm)Market cap ÷ TTM revenue.: 5.4×2016-09 5.502026-09 5.35-2.6% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 17.5×2016-09 4.032026-09 17.45+332.8% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 20.0×2016-09 14.412026-09 20.05+39.1% over the window
EV/EBITDA (fy): 15.4×
EV/Sales (ttm): 6.5×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 4.99%2016-06 7.1%2026-06 5.2%-27.2% over the window
Dividend yield (fwd)Indicated forward annual dividend ÷ current price — the rate the company has announced, not what was actually paid over the past year.: 1.97%
Dividend/share (fwd): $7.42
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 540.6M ÷ 538.4M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -0.42%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-0.42%) + dividends paid over that year ($5.3B) ÷ market_cap_at(2025-06-30) ($150.3B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 3.09%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($204B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2016-06 1.7%2026-06 0.0%-100.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $5.3B) ÷ today's market cap ($204B). Same caveat as the cash buyback yield.: 2.59%2016-06 3.9%2026-06 2.7%-30.8% over the window

Vs own 10Y history

P/E: 67th
P/OI: 75th
P/S: 61st
P/B: 55th
P/FCF: 84th

Bar = where today’s multiple sits in AMGN’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · windows as of 2026-09-11

-1.34%

-15.03%

-8.80%

+7.20%

YTD

+17.65%

+39.25%

+95.11%

Financial statements

Open full AMGN financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-8.44%	-0.65%
JNJ	Johnson & Johnson	+2.31%	-0.29%
ABBV	AbbVie Inc.	+3.36%	+0.83%
MRK	Merck & Co. Inc.	+8.28%	-0.54%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-6.53%	-2.37%
TMO	Thermo Fisher Scientific Inc.	+1.13%	+1.10%
GILD	Gilead Sciences Inc.	+5.78%	-0.75%
ABT	Abbott Laboratories	-8.08%	-1.36%

Amgen Inc. (AMGN) trades at $377.35 with a live price and an interactive chart covering 43+ years of daily price history, plus key valuation metrics. ChartRow also publishes AMGN’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full AMGN financial statements →

AMGN — Amgen Inc. price, chart and key statistics